Long-term safety and tolerability of subretinal transplantation of embryonic stem cell-derived retinal pigment epithelium in Asian Stargardt disease patients
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Background: Although human embryonic stem cells (hESCs) have been considered a potential therapeutic option for regenerative medicine, there are some concerns regarding tumorigenicity, immunogenicity and ethical considerations. Stargardt macular dystrophy (SMD) is the most common form of juvenile macular degeneration that causes early onset blindness. Therapeutic options for SMD remain limited, although several treatment strategies are currently under investigation. Here, we report a 3-year assessment of a phase I clinical trial involving subretinal transplantation of hESC-retinal pigment epithelium (RPE) cells in patients with SMD. Methods: This prospective, non-randomised clinical trial included three patients with SMD. All transplant recipients had central visual acuity no better than 20/400. Trans-pars plana vitrectomy was performed in the eye with poorer vision. RPE cells were reconstituted in balanced salt solution plus, then injected into the subretinal space using a semi-automated subretinal injection method. Results: No serious adverse events occurred throughout the 3-year period following the injection of hESC-RPE cells. The functional and anatomical results were favourable, compared with the natural course of SMD reported in the ProgStar study. One patient showed best-corrected visual acuity improvement, while the other patients had stable best-corrected visual acuity during the 3-year follow-up period. Conclusion: These results suggest the long-term safety, tolerability, and feasibility of subretinal hESC-derived RPE cell transplantation in regenerative medicine. Trial registration number: NCT01625559.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While a recent trial by Sung et al.87 reported short-term safety and improved outcomes as a result of treatment with ESC-derived retinal pigment epithelium (RPEs)”
From Induced pluripotency in the context of stem cell expansion bioprocess development, optimization, and manufacturing: a roadmap to the clinic (2021) · cites this paper as [87]
In the citing paper
“The most prominent difference between these two trials is the use of allogeneic ESC-derived RPEs in the Sung trial, versus autologous iPSC-derived RPEs in the Mandai trial.”
From Induced pluripotency in the context of stem cell expansion bioprocess development, optimization, and manufacturing: a roadmap to the clinic (2021) · cites this paper as Sung et al. [87]
In the citing paper
“While a recent trial by Sung et al.87 reported short-term safety and improved outcomes as a result of treatment with ESC-derived retinal pigment epithelium (RPEs)”
From Induced pluripotency in the context of stem cell expansion bioprocess development, optimization, and manufacturing: a roadmap to the clinic (2021) · cites this paper as Sung et al. [87]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schwartz, S. D., Regillo, C. D., Lam, B. L., Eliott, D., Rosenfeld, P. J., Gregori, N. Z., Hubschman, J.-P., Davis, J. L., Heilwell, G., Spirn, M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61376-3 · Cited by 1,327
Song, W. K., Park, K.-M., Kim, H.-J., Lee, J. H., Choi, J., Chong, S. Y., Shim, S. H., Del Priore, L. V., & Lanza, R. (2015) · Stem Cell Reports · doi:10.1016/j.stemcr.2015.04.005 · Cited by 393
Self-citationEmerging therapies for inherited retinal degeneration
Scholl, H. P. N., Strauss, R. W., Singh, M. S., Dalkara, D., Roska, B., Picaud, S., & Sahel, J.-A. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf2838 · Cited by 219
Sun~er, I. J., Kokame, G. T., Yu, E., Ward, J., Dolan, C., & Bressler, N. M. (2009) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.08-3225 · Cited by 170
Research works printed but not linked: 24
- 10.1016/S0896-1549(01)00011-6 · DOI
- Strauss, 2016, The natural history of the progression of atrophy secondary to Stargardt disease (progstar) studies: design and baseline characteristics: progstar report no. 1, Ophthalmol, 123, 817, 10.1016/j.ophtha.2015.12.009 · DOI · Paper page
- 10.1136/bjophthalmol-2016-308823 · DOI · Paper page
- 10.1152/physrev.00021.2004 · DOI · Paper page
- 10.1016/j.preteyeres.2006.12.002 · DOI · Paper page
- 10.1002/stem.149 · DOI · Paper page
- 10.1016/S0140-6736(05)66473-2 · DOI · Paper page
- Volarevic, 2018, Ethical and safety issues of stem cell-based therapy, Int J Med Sci, 15, 36, 10.7150/ijms.21666 · DOI · Paper page
- 10.1161/CIRCRESAHA.111.249243 · DOI
- 10.1167/iovs.15-18681 · DOI · Paper page
- Mehat, 2018, Transplantation of human embryonic stem cell-derived retinal pigment epithelial cells in macular degeneration, Ophthalmol, 125, 1765, 10.1016/j.ophtha.2018.04.037 · DOI · Paper page
- Kwon, 2019, Semiautomated subretinal fluid injection method using viscous fluid injection mode, Retina, 39, S174, 10.1097/IAE.0000000000002025 · DOI
- Sung, 2019, Clinical and genetic characteristics analysis of Korean patients with Stargardt disease using targeted exome sequencing, Ophthalmol, 241, 38, 10.1159/000490073 · doi:10.1159/000490073
- Strauss, 2017, Progression of Stargardt disease as determined by fundus autofluorescence in the retrospective progression of Stargardt disease study (progstar report no. 9), JAMA Ophthalmol, 135, 1232, 10.1001/jamaophthalmol.2017.4152 · DOI · Paper page
- Kuehlewein, 2016, Comparison of manual and semiautomated fundus autofluorescence analysis of macular atrophy in Stargardt disease phenotype, Retina, 36, 1216, 10.1097/IAE.0000000000000870 · DOI
- 10.1097/IAE.0b013e3181cd48b0 · DOI
- Leung, 2016, Retinal detachment after subretinal stem cell transplantation, Ophthalmic Surg Lasers Imaging Retina, 47, 600, 10.3928/23258160-20160601-16 · DOI
- Kruger, 2002, Proliferative vitreoretinopathy after trauma, Int Ophthalmol Clin, 42, 129, 10.1097/00004397-200207000-00015 · doi:10.1097/00004397-200207000-00015
- Shim, 2017, Survival of transplanted human embryonic stem cell: derived retinal pigment epithelial cells in a human recipient for 22 months, JAMA Ophthalmol, 135, 287, 10.1001/jamaophthalmol.2016.5824 · DOI
- Anderson, 1981, The onset of pigment epithelial proliferation after retinal detachment, Invest Ophthalmol Vis Sci, 21, 10
- 10.1001/archopht.122.5.758 · DOI · Paper page
- 10.1001/archopht.121.4.531 · DOI · Paper page
- 10.1016/j.ophtha.2004.06.035 · DOI
- 10.1097/00006982-200002000-00009 · DOI · Paper page
Cited by
Colter, J., Murari, K., Biernaskie, J., & Kallos, M. S. (2021) · npj Regenerative Medicine · doi:10.1038/s41536-021-00183-7 · Cited by 33
Metadata
- Authors
- Sung, Y., Lee, M. J., Choi, J., Jung, S. Y., Chong, S. Y., Sung, J. H., Shim, S. H., & Song, W. K.
- Venue
- British Journal of Ophthalmology
- Publisher
- BMJ
- Published
- 2020-07-29
- Volume
- 105
- Issue
- 6
- Pages
- 829-837
- ISSN
- 0007-1161
- 1468-2079
- Cited by
- 66
- References
- 4
- Language
- en
- Funders
- Ministry of Health & Welfare, Republic of Korea (HI12C0447(A120506))
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-term safety and tolerability of subretinal transplantation of embryonic stem cell-derived retinal pigment epithelium in Asian Stargardt disease patients. https://app.cochat.ai/papers/10.1136/bjophthalmol-2020-316225
- The paper
- Sung, Y., Lee, M. J., Choi, J., Jung, S. Y., Chong, S. Y., Sung, J. H., Shim, S. H., & Song, W. K. (2021). Long-term safety and tolerability of subretinal transplantation of embryonic stem cell-derived retinal pigment epithelium in Asian Stargardt disease patients. British Journal of Ophthalmology. https://doi.org/10.1136/bjophthalmol-2020-316225
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.